Ohio is currently home to 3322 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A QoL Intervention for Young African American Breast Cancer Survivors
NCT05452681
Recruiting
The purpose of this two-arm pilot RCT is to evaluate processes and preliminary outcomes of a targeted QOL intervention vs. an attention control among young AA survivors post-treatment for early (I-II) & late (III) stage breast cancer.
Gender:
Female
Ages:
Between 18 years and 44 years
Trial Updated:
02/06/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Breast Cancer, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Register for Updates
Validation of a Salivary miRNA Diagnostic Test for ASD
NCT05418023
Recruiting
This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developin... Read More
Gender:
All
Ages:
Between 18 months and 7 years
Trial Updated:
02/06/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Autism Spectrum Disorder, Developmental Delay
Register for Updates
A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer
NCT05243056
Recruiting
This clinical trial studies the use of a quality of life intervention called Y-AMBIENT to help young African American with stage I-III breast cancer manage daily life. Y-AMBIENT is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. The Y-AMBIENT intervention may improve quality of life and other health-related outcomes in young African American breast cancer survivors.
Gender:
Female
Ages:
Between 18 years and 44 years
Trial Updated:
02/06/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Register for Updates
SLSMDS Natural History Study
NCT05029843
Recruiting
The Single Large-Scale mtDNA Deletion Sydrome: Natural History Study (PS-NHS) aims to collect data on standardized clinical outcomes, store data on the Champ Foundation Registry (CFR) and make this data available to researchers, clinicians, and industry partners who are studying SLSMDS to answer questions regarding the disease, including its causes, potential treatments, and other topics. A secondary aim is to analyze the data to understand research questions relating to the natural history of S... Read More
Gender:
All
Ages:
All
Trial Updated:
02/06/2023
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Pearson Syndrome, Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)
Register for Updates
Study of Infigratinib in Children With Achondroplasia
NCT04265651
Recruiting
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK S... Read More
Gender:
All
Ages:
Between 3 years and 11 years
Trial Updated:
02/06/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Achondroplasia
Register for Updates
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Venous Thromboembolism
Register for Updates
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
NCT05428852
Recruiting
This pilot study will be a single center, randomized controlled study of 24 participants with diagnosed BM (various primary disease sites) comparing the effect of a ketogenic (n=12) and AICR (n=12) diet. Potential participants will be identified via medical record reviews and chart reviews. Eligibility of patients will be assessed via medical record review. Randomization will be balanced by blocks of random sizes but no stratification due to the small sample size. Both groups will undergo a 16-w... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Brain Metastases, Adult
Register for Updates
Stress Hydrocortisone In Pediatric Septic Shock
NCT03401398
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days follo... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
02/02/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Septic Shock
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Columbus, Columbus, Ohio
Conditions: Colorectal Cancer
Register for Updates
ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study
NCT04149509
Recruiting
The objective of this longitudinal cohort study is to quantify the effects of antenatal opioid exposure on the trajectory of brain development over the first 2 years of life, examine associations with developmental and neurobehavioral outcomes, and explore how specific factors (differing antenatal and postnatal exposures, severity of neonatal opioid withdrawal, maternal stress/depression/parenting) modify these effects
Gender:
All
Ages:
1 month and below
Trial Updated:
01/31/2023
Locations: Cincinnati Children's Medical Center, Cincinnati, Ohio
Conditions: Neonatal Opioid Withdrawal Syndrome
Register for Updates
Psychologically Informed Education Intervention for Adolescents With Atraumatic Lower-Extremity Injuries
NCT05701618
Recruiting
This is a randomized prospective study assessing the impact of psychosocial factors on pain and physical performance among adolescents with leg pain. A set of psychosocial surveys assessing activity-related fear, stress, anxiety and depression will be completed by the participants. Participants will then complete self-report questionnaires assessing pain, quality of life and functional ability followed by an assessment of physical activity levels assessed with a wearable activity monitor;. Parti... Read More
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
01/30/2023
Locations: Nationwide Children's Hospital Sports and Ortho Physical Therapy, Columbus, Ohio
Conditions: Leg Injury
Register for Updates
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Clinical Research Solutions, Cleveland, Ohio
Conditions: Bladder Cancer
Register for Updates